Featured Education

On Demand Activities

More results...

Therapeutics Areas
Learner Specialties
Expires After
  • On-Demand
Checkpoint Conversations: Integrating Immune Checkpoint Inhibitors in Hodgkin Lymphoma
  • Credit: 0.51hr(s)
  • AAPA, ABIM, CME, CPE, MOC, NCPD, Royal College MOC 
  • May 15, 2024 — 
  • May 14, 2025
  • Therapeutic Areas: Pan Tumor, Pathology, Pharmacy
  • Specialties: Pathology, Pharmacy
  • Location: Internet Activity Enduring
In this fourth episode, “Checkpoint Conversations: Integrating Immune Checkpoint Inhibitors in Hodgkin Lymphoma,” from the 4-part series Med Table Talk, “The Power of the Community: Translating Innovations into Care in NHL and HL,” join expert faculty as they discuss the benefit of immune checkpoint inhibition for the treatment of HL in patients with relapsed/refractory disease. Discussions will also circulate around how interdisciplinary teams can assist with coordination of patient care, including clinical trials and access to appropriate treatment for those in underrepresented communities.
Access Course
  • On-Demand
The Evolution of HCT, Part 3: Donor Availability
  • Credit: 0.75hr(s)
  • CME, NCPD
  • February 22, 2024 — 
  • February 20, 2025
  • Therapeutic Areas: Hematologic Oncology, Hematology, Hematopoietic Cell Transplantation (HCT), Oncology
  • Specialties: Bone Marrow Transplantation, Hematology, Oncology
  • Location: Internet Activity Enduring
Community hematology/oncology practices play a critical role to expand patient access to hematopoietic cell transplantation (HCT) and improve patient outcomes. This self-guided online training course series consists of five courses designed to present the current state of the science for Hematopoietic Cell Transplantation (HCT) by following the evolution of HCT over time. The series is broken down into major misperceptions or myths about HCT and cellular therapy that are not supported by current research and clinical practice. This is Part 3 in a 5-part series, covering advances in donor availability that have led to expanded access to HCT over time.
Access Course
  • On-Demand
Enhancing Patient Care for CAR T-Cell Therapy in NHL: Comprehensive Solutions for Your Community
  • Credit: 1.0hr(s)
  • ABIM, CME, IPCE, MOC, NCPD, Royal College MOC 
  • June 15, 2024 — 
  • June 14, 2025
  • Therapeutic Areas: Chronic Lympoblastic Leukemia (CLL)
  • Specialties: Mantle Cell Lymphoma
  • Location: Internet Activity Enduring
In this Build Your Own Case Study | Enhancing Patient Care for CAR T-Cell Therapy in NHL: Comprehensive Solutions for Your Community, learn from expert faculty about the most recent clinical updates and emerging real-world efficacy and safety data of CAR T-cell therapies in NHL. Build Your Own Case Study will guide participants through an interactive learning progression, as they go through two patient scenarios and make selections at critical decision points. Participants will be provided with patient clinical presentation and other relevant factors including age, time and aggressiveness of relapse, social history, genetic profiling/molecular testing results, cytogenetic risk factors, disease subtype, comorbidities, and prior therapies in order to make appropriate treatment decisions. Expert faculty will discuss participant selection of treatments, sequencing considerations, and drug-related toxicities. The activity will conclude with a discussion on how to develop strategies to assist patients with coordinated care and long-term disease management after the receipt of CAR T-cell therapy. This ancillary educational activity is derived from the 2024 ASCO Annual Meeting, originally held on May 31, 2024
Access Course
  • On-Demand
Bridging the Gap to Reach Treatment Goals in DLBCL
  • Credit: 1.0hr(s)
  • AAPA, CME, CPE, NCPD
  • March 15, 2023 — 
  • February 28, 2024
  • Therapeutic Areas: Hematologic Oncology, Hematology
  • Specialties: CAR T-Cell Therapy, Lymphoma
  • Location: Internet Activity Enduring
Diffuse large B-cell lymphoma (DLBCL) is the most common type of non-Hodgkin lymphoma, which typically occurs in patients over the age of 60 years. While chemoimmunotherapy (R-CHOP) has been considered the first line treatment option, approximately 40% of patient with DLBCL will fail to respond and experience a relapse. Autologous hematopoietic stem cell transplantation (AHCT) has been used as treatment for patients who experience a relapse; however, many patients are ineligible for the procedure due to age, comorbidities, or resistance to second-line chemoimmunotherapy. Novel treatment options have thus been introduced to the treatment landscape of DLBCL, including chimeric antigen receptor T-cell therapy (CAR T) with trial results displaying sustained remissions for relapsed patients. Because the options for treatment of DLBCL have changed rapidly, it is important for treating physicians to be aware of the options that are available as well as assist them in overcoming barriers that may impact their treatment. Join us for this educational Med Table Talk® LIVE on Bridging the Gap to Reach Treatment Goals in DLBCL as our experts have a candid conversation about the available treatment options for DLBCL, how cellular therapists and community physicians must communicate to ensure adequate care between referring and treating physicians, and how to recognize and address common treatment barriers. This taped satellite symposium was derived from the 2023 Tandem Meetings | Transplantation & Cellular Therapy Meetings of ASTCTTM and CIBMTR® on February 18, 2023.
Access Course
  • On-Demand
Effective Strategies for Improving Vaccine Uptake
  • Credit: 0.50hr(s)
  • AAFP, AAPA, ABIM, CME, IPCE, MOC, NCPD, Royal College MOC 
  • June 28, 2024 — 
  • June 27, 2025
  • Therapeutic Areas: Family Medicine / Primary Care
  • Specialties: Primary Care
  • Location: Internet Activity Enduring
Healthcare providers (HCPs) encounter significant challenges in vaccine acceptance. A critical need exists among primary care providers (PCPs) to remain abreast of the continuously evolving vaccination landscape. As such, PCPs need to be able to evaluate the burden of vaccine-preventable diseases, provide well-founded recommendations for vaccine measures, and apply appropriate strategies to address vaccine hesitations.
Access Course
  • On-Demand
Effective Strategies for Shared Decision-Making in T2D Care
  • Credit: 0.50hr(s)
  • AAFP, AAPA, ABIM, CME, IPCE, MOC
  • April 30, 2024 — 
  • October 31, 2025
  • Therapeutic Areas: Diabetes, Family Medicine / Primary Care, Obesity
  • Specialties: Diabetes, Endocrinology, Obesity, Primary Care
  • Location: Internet Activity Enduring
Healthcare providers (HCPs) encounter significant challenges when treating patients with type 2 diabetes (T2D). HCPs should be cognizant of when to change or intensify treatment and be aware of options that are non-optimal. As such, HCPs need to be equipped with current professional guidelines, the latest clinical evidence on new and emerging therapies for T2D, and strategies for engaging patients in shared decision-making to effectively prioritize weight management and promote comprehensive T2D care.
Access Course
View All MLI Activities
Facebook Twitter Linkedin Instagram
Subscribe to Mailing List
Scroll to Top